Carlos Arteaga, MD, discusses the resistance to CDK4/6 inhibitors in estrogen receptor–positive breast cancer.
Carlos Arteaga, MD
Advertisement
Articles by Carlos Arteaga, MD
Carlos L. Arteaga, MD, associate director for Clinical Research, director, Center for Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center, discusses some of the ongoing trials exploring treatments for patients with metastatic breast cancer.
Advertisement
Latest Updated Articles
Dr. Arteaga on Ongoing Trials in Metastatic Breast CancerPublished: August 9th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5